Anxiety does not always look like a panic attack. Sometimes it is quieter: replaying conversations long after they have ended, struggling to switch off at night, feeling physically tense when nothing is obviously wrong, or finding it difficult to concentrate because part of your attention is constantly occupied by worry.
For people who experience that kind of persistent tension, one question comes up frequently: is it possible to calm the nervous system without simply feeling sedated?
That question helps explain the growing interest in Selank, a synthetic peptide studied for potential effects on anxiety, stress and cognitive function. Unlike many peptides currently discussed online, Selank has also been evaluated directly in people with anxiety disorders.
While academic and clinical research on Selank is still ongoing, human studies into how it works on the brain provide a useful foundation for understanding its potential effects on anxiety, stress regulation and brain signaling.
What is Selank?
Selank is a synthetic peptide made from seven amino acids. It was developed by Russian researchers from tuftsin, a naturally occurring peptide involved in immune function. Over time, however, researchers became interested in Selank for a very different reason: its effects on the nervous system.
It began to be studied as an anxiolytic – a compound intended to reduce anxiety. What makes Selank particularly interesting is that it does not appear to act as a conventional stimulant or sedative. Instead, research suggests that it may influence several signaling systems involved in the way the brain regulates anxiety and responds to stress.
One of the most important of those systems involves GABA.
Why GABA matters in anxiety
The brain is constantly balancing signals that increase neuronal activity with signals that reduce it. GABA, short for gamma-aminobutyric acid, is the brain’s primary inhibitory neurotransmitter. One useful way to think about it is as part of the nervous system’s braking mechanism.
When GABA activates its receptors, neuronal activity generally decreases. This helps regulate arousal, stress responses and the tendency of neural circuits to become excessively active. That is one reason the GABA system is so closely connected with anxiety.
Some established anti-anxiety medications act directly on this pathway. Benzodiazepines such as diazepam, for example, enhance GABA activity at specific receptors, producing a relatively rapid calming effect.
Selank appears to interact with the broader GABA system too, but not in the same way.
Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences published a 2016 study showing that Selank altered the expression of numerous genes involved in neurotransmission, including changes that overlapped with GABA-related activity. Other laboratory research has suggested that Selank may also affect GABA receptor binding through positive allosteric modulation.
Has Selank actually been tested in people with anxiety?
Yes, and this is one of the more important distinctions between Selank and many experimental peptides.
One of the key human studies about Selank, published in 2008, in people with generalized anxiety disorder and neurasthenia and compared it with medazepam, a benzodiazepine anxiolytic. Researchers measured symptoms using established clinical tools, including the Hamilton Anxiety Rating Scale, the Zung scale and the Clinical Global Impression scale.
The study reported anxiolytic effects with both Selank and medazepam. Researchers also described changes related to fatigue and mental activity among people receiving Selank.
The study was conducted as part of a broader Russian research program investigating Selank’s neurological effects. It gives Selank something many experimental peptides do not have: clinical research conducted directly in people experiencing anxiety disorders.
A second comparison: Selank vs. phenazepam
Six years later, researchers compared Selank with phenazepam, another benzodiazepine used in the treatment of anxiety disorders. Participants included people with anxiety-phobic disorders, generalized anxiety and somatoform disorders.
Researchers reported a pronounced anxiolytic effect with Selank, alongside what they described as mild nootropic effects. They also reported that the anxiolytic effect continued for approximately one week after the final administration used in the study.
Taken together with the 2008 trial, this added another direct clinical data point in people with anxiety disorders, with changes measured using established symptom scales.
Selank may be doing more than influencing GABA
Anxiety is not controlled by a single neurotransmitter. The brain’s stress and anxiety systems involve interactions between GABA, serotonin, dopamine, endogenous opioid peptides, stress hormones and multiple neural circuits.
Research suggests that Selank may influence several parts of this wider network. One area of particular interest is the enkephalin system.
Enkephalins are naturally occurring peptides that interact with opioid receptors and participate in processes including pain regulation, emotional responses and stress. Research involving people with anxiety disorders has found altered enkephalin metabolism and has suggested that Selank may slow the breakdown of these naturally occurring peptides.
The 2008 clinical study also reported changes in enkephalin activity during Selank treatment, particularly among participants with generalized anxiety disorder.
What about everyday stress?
Stress and anxiety overlap, but they are not the same thing. Stress is a biological response to a demand or perceived threat. It can increase heart rate, alter attention, raise muscle tension, change hormone levels and affect neurotransmitter activity.
In the short term, that response is useful. It prepares the body to deal with a challenge. The problem arises when the stress response remains activated for too long, or becomes disproportionately strong in situations that do not require it.
Researchers increasingly describe this in terms of stress resilience: the nervous system’s ability to respond to stress, adapt and then return toward its normal state. GABA, serotonin, neuropeptides and the hypothalamic-pituitary-adrenal axis all contribute to that process.
Because Selank appears to interact with several of these signaling systems, researchers have also investigated whether it can alter the nervous system’s response under chronic stress. Experimental studies have reported changes in anxiety-related behavior under chronic stress conditions, as well as interactions between Selank and conventional GABAergic drugs.
That does not mean Selank has been proven to make someone resistant to stress. What it does suggest is that its potential effects may extend beyond a simple “calming” action and into some of the broader systems involved in regulating the stress response.
Does Selank work like a benzodiazepine?
Selank and benzodiazepines both interact with pathways related to GABA, but research suggests they do so in different ways.
Benzodiazepines act directly on specific sites of GABA-A receptors, enhancing GABA’s calming activity in the nervous system. Selank appears to influence the GABA system more indirectly, with research exploring effects on gene expression, receptor activity and other signaling processes involved in anxiety and stress regulation.
This different mechanism is one of the reasons Selank has attracted scientific interest. Researchers are exploring whether influencing these broader regulatory pathways could offer another way of supporting the brain’s response to anxiety and stress.
So, can Selank help with anxiety?
There is human clinical evidence suggesting that Selank has anxiolytic activity. Clinical studies have reported reductions in anxiety symptoms, including research comparing Selank with conventional anxiolytic medications.
The mechanistic studies described above give that clinical signal a plausible biological framework rather than relying on a single proposed pathway.
That puts Selank in a more interesting scientific position than a peptide supported only by theoretical mechanisms or animal research.
The limitations matter. Much of the clinical literature comes from a relatively concentrated group of researchers and institutions, and Selank has not gone through the large, international clinical-development programs associated with established anxiety treatments. So while the evidence is intriguing, it remains a developing area of research rather than a settled one.
Anxiety is rarely one chemical being “out of balance”
It is tempting to explain anxiety through a single biological problem: too little GABA, too much cortisol, not enough serotonin. Human biology is rarely that simple.
Anxiety emerges from interactions between brain circuits, neurotransmitters, hormones, genetics, previous experiences, sleep, physical health and the environment around us. That is why two people who both describe themselves as “anxious” may be dealing with very different problems.
Occasional periods of stress are not the same as generalized anxiety disorder. Panic attacks are not the same as trauma-related symptoms. And chronic psychological stress may require a different approach again.
Where Fitstar comes in
Peptide therapy is about more than choosing a compound. Fitstar uses your health profile, goals and medical history to create a preliminary peptide protocol that can then be reviewed with a licensed clinician.
When peptide therapy is appropriate and available, Fitstar can also help you manage your protocol, follow your experience over time and stay connected with your care team.
Because with something as complex as anxiety or chronic stress, understanding the system is often more useful than simply chasing a calming effect.
Sources & further reading
Zozulia AA, et al. (2008). Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in the therapy of generalized anxiety disorders and neurasthenia.Randomized clinical research comparing Selank with medazepam. PubMed
Medvedev VE, et al. (2014). A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders. PubMed
Medvedev VE, et al. (2015). Optimization of the treatment of anxiety disorders with Selank. Research examining Selank in combination with phenazepam. PubMed | DOI (in Russian)
Volkova A, et al. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. Full text | PubMed
Vyunova TV, et al. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein & Peptide Letters. PubMed | DOI (in Russian)
Zozulya AA, et al. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. PubMed | DOI (in Russian)
Kupcova I, et al. (2022). Anxiety and Depression: What Do We Know of Neuropeptides? Behavioral Sciences. Review examining neuropeptide signaling in anxiety, depression and stress adaptation. Full text | PubMed